MIRA
INFORM REPORT
|
Report Date : |
08.08.2007 |
IDENTIFICATION DETAILS
|
Name : |
ALBERT DAVID LIMITED |
|
|
|
|
Registered Office : |
15, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2007 |
|
|
|
|
Date of Incorporation : |
16.11.1938 |
|
|
|
|
Com. Reg. No.: |
009490 |
|
|
|
|
CIN No.: [Company
Identification No.] |
L511009WB1938PLC009494 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
CALA00279G |
|
|
|
|
Legal Form : |
It is a Public Limited Liability Company. The company’s shares are listed on the Stock Exchanges. |
|
|
|
|
Line of Business : |
The company is engaged in manufacturing of pharmaceutical formulations including amino acid infusions. The company also manufactures disposable syringes and needles and a wide range of bulk drugs. It is recognised as a large IV fluid manufacturer, both in glass and polyethylene containers. |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 1884800 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well-established and reputed pharmaceutical company having satisfactory track. Directors are reported as experienced, respectable and resourceful industrialists. Their trade relations are reported as fair. General financial position is satisfactory. Payments are usually correct and as per commitments |
LOCATIONS
|
Registered Office : |
15, |
|
Tel. No.: |
91-33-2273 9000 / 2273 9001/2273 9002 /2225 6442/2225 6422 / 2212-9700/9637/9592 |
|
Fax No.: |
91-33-2225- 8714 / 2212-9629 |
|
E-Mail : |
3. adidavid@giasdl01.vsnl.net.in 5.
adldavid@dataone.in |
|
website : |
|
|
|
|
|
|
Kumhar, |
|
Tel. No.: |
91-2354601 |
|
Fax No.: |
91-612 2368263 |
|
E-Mail : |
adlpatna@sancharnet.in |
|
|
|
|
Vijaywada Office : |
30-20/3-15/ Vijaywada – 520 002 |
|
Tel. No.: |
91-243 9793 |
|
Fax No.: |
91- 866 2439862 |
|
E-Mail : |
albertdavid@rediffmail.com |
|
|
|
|
Factory 1 : |
Ø
5/11, Tel. No. 91-33-2557 1131 / 123 / 1281 Fax No. 91-33-2557 1181 E-mail hpkid@cal.vsnl.net.in Ø
B-12/13, Tel. No. 91-575-2750070 / 71 / 72 /120 2750873 Fax No. 91-575-2750073 E-mail adidavid@giasdl01.vsnl.net.in / adlgzb@sify.com Ø Plot No. 207, New Industrial Area No.2, Mandideep – 462 048, Dist. Raisen, Madhya Pradesh Tel. No. 91-7480-233013 / 232203 / 233703 Fax No. : 91-9780 / 7480- 503226 E-mail: adidavid@mantrafreenet.com. |
|
|
|
|
Branches : |
Ø
22/Zone 1, Maharana Pratap Nagar, Tel. No. 91-755-2554911 Fax No. 91-755-2554633 E-mail adldavid@bom6.vsnl.net.in Ø
21, Gopal Chandra Bose Lane, Kolkata – 700
050, Tel. No. 91-33-2557 4471 / 3556 9799 E-mail: adfact@dataone.in Ø
110, Tel. No. 91-44-2374 0811/4242 Fax No. 91-44-2374 0911 E-mail adltdmas@giasmd01.vsnl.net.in Ø
4/11, Tel. No. 91-11-2327 0220/0261 Fax No. 91-11-2328 2675 E-mail adidavid@nda.vsnl.net.in Ø
Tel. No. 91-361-2513085 / 2451693 / 2513085 / 2451893 Ø
Sandilla House, 4, Tel. No. 91-522-2455705 Fax No. 91-522-2451306 E-mail adl@lwl.vsnl.net.in Ø
101, Maket Chamber No. 4, 10th
Floor, Nariman Point, Mumbai – 400 021, Tel. No. 91-22-2204 4179/22023868 Fax No. 91-22-2285 5458 E-mail adidavid@bom4.vsnl.net.in |
DIRECTORS
|
Name : |
Shri H. P. Kabra |
|
Designation : |
President (Commercial) |
|
|
|
|
Name : |
Shri S. C. Shah |
|
Designation : |
Vice President (Finance) |
|
|
|
|
Name : |
Shri L. K. Wadhawan |
|
Designation : |
Vice President (Sales and Marketing) |
|
|
|
|
Name : |
Dr. M. K. Maheshwari |
|
Designation : |
Vice President (Personnel and Legal Affairs) |
|
|
|
|
Name : |
Shri P. K. Jain |
|
Designation : |
Vice President (Works), Kolkata |
|
|
|
|
Name : |
Dr. G. P. Srivastava |
|
Designation : |
Vice President (Technical), Kolkata |
|
|
|
|
Name : |
Dr. D. P. Ghosh |
|
Designation : |
Senior Vice President (Technical) – cum- Factory, Manager,
|
|
|
|
|
Name : |
Shri D. Chitlangia |
|
Designation : |
General Manager (Commercial), |
|
|
|
|
Name : |
Shri V. K. Chaudhary |
|
Designation : |
General Manager (Technical), Mandideep |
|
|
|
|
Name: |
Shri Manish Tandon |
|
Designation: |
General Manager (Commercial), Mandideep |
|
|
|
|
Name: |
Dr. Indrajit Dhar |
|
Designation: |
Company Secretary |
|
|
|
|
Name : |
Mr. A.K. Kothari |
|
Designation : |
Chairman |
|
|
|
|
Name : |
Mr.Indrajit Dhar |
|
Designation : |
Company Secretary |
|
|
|
|
Name : |
Mr.D D Binani |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr.P L Agrawal |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr.Hemal Kampani |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr.Rajeev Singhi |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr.A V Iyengar |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr.K P Mundhra |
|
Designation : |
Executive Director |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
|
Names of Shareholders |
No. of Shares |
Percentage of
Holding |
|
PROMOTERS HOLDINGS |
|
|
|
Indian Promoters |
816,740 |
14.31 |
|
Person Acting in Concert |
3,155,519 |
55.29 |
|
NON-PROMOTERS
HOLDINGS |
|
|
|
Institutional Investors |
|
|
|
Mutual Funds and UTI |
7,350 |
0.13 |
|
Banks Fin. Inst. and Insurance |
144,691 |
2.54 |
|
Other Investors |
|
|
|
Private Corporate Bodies |
74,713 |
1.31 |
|
NRI’s/OCB’s/Foreign Others |
8,075 |
0.14 |
|
General Public |
1,500,074 |
26.28 |
|
TOTAL |
5,707,162 |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
The company is engaged in manufacturing of pharmaceutical formulations including amino acid infusions. The company also manufactures disposable syringes and needles and a wide range of bulk drugs. It is recognised as a large IV fluid manufacturer, both in glass and polyethylene containers. |
||||||||||
|
|
|
||||||||||
|
Products : |
|
PRODUCTION STATUS
|
Particulars |
|
|
Units |
Installed
Capacity |
|
Non-Sterile
Liquid Elixir & Vitamin |
|
|
K.L. |
1450.00 |
|
Ointment |
|
|
M.T. |
2.00 |
|
Tablets |
|
|
Millions |
663.650 |
|
Sterile
Injectible |
|
|
K.L. |
23273.20 |
|
Powders &
Granules |
|
|
M.T. |
147.50 |
|
Capsules |
|
|
Millions |
225.000 |
|
Bulk Drugs |
|
|
M.T. |
175.00 |
|
Disposable
Syringes |
|
|
Millions |
72.000 |
|
Disposable
Needles & Parts |
|
|
Millions |
100.000 |
|
Disposable
Syringes & Needles |
|
|
Millions |
-- |
GENERAL INFORMATION
|
No. of Employees : |
500 |
|
|
|
|
Bankers : |
State Bank of |
|
|
|
|
Facilities : |
Secured by hypothecation of inventories and book debts and charge on fixed assets of the company and personal guarantee of a director of the company. |
|
|
|
|
Banking
Relations : |
Satisfactory |
|
|
|
|
Auditors : |
G. Basu & Company Chartered Accountants |
|
|
|
|
Associates/Subsidiaries : |
Ø N. P. Veneer and Saw Mills Limited Ø Kothari and Company Private Limited Ø Commercials House Private Limited Ø Kothari Investment and Industries Private Limited Ø Jedy’s Commercial Bureau Private Limited Ø Vishnuhari Investment and Properties Limited Ø Karunasindhu Finances and Investment Limited Ø Satkriti Investment Limited Ø Vernacular Vyapar Limited |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
9700000 |
Equity Shares |
Rs. 10 Each |
Rs. 97.000 millions |
|
|
|
|
|
|
300000 |
Preference Shares |
Rs. 10 Each |
Rs. 3.000 millions |
|
|
Total: |
|
Rs.100.000 millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
5707162 |
Equity Shares |
Rs. 10 Each |
Rs. 57.072 Millions |
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2007 |
31.03.2006 |
31.03.2005 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
57.100 |
57.100 |
57.072 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
414.100 |
302.100 |
244.229 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
471.200 |
359.200 |
301.301 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
294.800 |
233.500 |
201.518 |
|
|
2] Unsecured Loans |
84.500 |
64.600 |
70.933 |
|
|
TOTAL BORROWING |
379.300 |
298.100 |
272.451 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
0.000 |
8.536 |
|
|
|
|
|
|
|
|
TOTAL |
850.500 |
657.300 |
582.288 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
436.900 |
309.100 |
169.559 |
|
|
Capital work-in-progress |
120.000 |
57.500 |
7.893 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.100 |
0.100 |
0.102 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
5.949 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
343.100
|
239.400 |
256.681 |
|
|
Sundry Debtors |
175.400
|
113.700 |
138.085 |
|
|
Cash & Bank Balances |
50.300
|
113.900 |
174.197 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
314.200
|
255.300 |
39.225 |
|
Total
Current Assets |
883.000
|
722.300 |
608.188 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
325.500
|
221.700 |
183.538 |
|
|
Provisions |
264.000
|
210.000 |
25.865 |
|
Total
Current Liabilities |
589.500
|
431.700 |
209.403 |
|
|
Net Current Assets |
293.500
|
290.600 |
398.785 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
850.500 |
657.300 |
582.288 |
|
PROFIT & LOSS ACCOUNT
|
PARTICULARS |
31.03.2007 |
31.03.2006 |
31.03.2005 |
|
|
Sales Turnover |
1663.000 |
1370.600 |
1116.5 |
|
|
Other Income |
88.100 |
37.900 |
30.200 |
|
|
Total Income |
1841.900 |
1377.200 |
1048.203 |
|
|
|
|
|
|
|
|
Profit/(Loss) Before Tax |
207.600 |
118.700 |
66.266 |
|
|
Provision for Taxation |
75.600 |
44.500 |
24.216 |
|
|
Profit/(Loss) After Tax |
132.000 |
74.200 |
42.050 |
|
|
|
|
|
|
|
Export Value
|
|
|
|
|
F.O.B Value of exports (including
deemed Export in Indian Currency Rs.7.080 millions, Previous Year Rs. 7.677
millions)
|
120.718 |
129.616 |
125.850 |
|
|
|
|
|
|
|
|
Imports Value: |
|
|
|
|
|
|
Capital Goods
|
11.801 |
111.889 |
25.066 |
|
|
Raw Materials and others
|
192.610 |
113.675 |
78.238 |
|
|
Spare Parts and Components
|
3.885 |
5.872 |
4.138 |
|
|
|
|
|
|
|
Total Imports |
|
|
|
|
|
|
|
|
|
|
|
Expenditures : |
|
|
|
|
|
|
Manufacturing Expenses |
0.000 |
0.000 |
463.527 |
|
|
Raw Material Consumed |
533.100 |
372.500 |
161.268 |
|
|
Interest |
29.300 |
15.000 |
0.000 |
|
|
Power & Fuel |
104.600 |
67.300 |
0.000 |
|
|
Depreciation & Amortization |
47.700 |
38.700 |
0.000 |
|
|
Other Expenditure |
919.600 |
765.000 |
832.137 |
|
Total Expenditure |
1634.300 |
1258.500 |
1456.932 |
|
QUARTERLY RESULTS
|
PARTICULARS |
|
|
30.06.2007 [1st
Quarter] |
Sales Turnover
|
|
|
458.300 |
Other Income
|
|
|
3.500 |
Total Income
|
|
|
461.800 |
Total Expenditure
|
|
|
390.000 |
Operating Profit
|
|
|
71.800 |
Interest
|
|
|
8.100 |
Gross Profit
|
|
|
63.700 |
Depreciation
|
|
|
12.300 |
Tax
|
|
|
19.600 |
Reported PAT
|
|
|
31.900 |
200706 Quarter 1 --------------- Notes Expenditure Includes
(Increase)/Decrease in stock in Trade Rs 53.369 millions Consumption of Raw
Material/Packing Material Rs 138.969 millions Staff Cost Rs 74.953 millions
Manufacturing, Administrative Selling & Distribution Expenses Rs 122.658
millions Tax Includes Provision for Current Tax Rs 18.500 millions Deferred Tax
Rs (0.074) million Fringe Benefit Tax Rs 1.100 millions EPS is Basic &
Diluted Status of Investor Complaints for the quarter ended June 30, 2007
Complaints Pending at the beginning of the quarter Nil Complaints Received
during the quarter 01 Complaints disposed off during the quarter 01 Complaints
unresolved at the end of the quarter Nil 1. The above financial results were
reviewed by Audit Committee and were taken on record at the meeting of the
Board of Directors held on July 31, 2007. 2. Based on the guiding principles
given in Accounting Standard on Segment Reporting (AS-17) issued by the
Institute of Chartered Accountants of India, the Company's primary business
Segment is Pharmaceuticals. As the Company's business activity falls within a
single primary business segment, the disclosure requirements of AS-17 in this
regard are not applicable. 3. In view of the Accounting Standard (AS) 15
(revised 2005) Employee Benefits issued by the Institute of Chartered
Accountants of India, which is applicable w.e.f. April 01, 2007, the
adjustment, if any, on account of transitional provision will be dealt with in
accordance with the accounting standard at the year end. Additional Charges of
Rs 0.230 million on estimated basis on account of employee benefit has been
provided for in the current year. 4. Depreciation on fixed assets of Kolkata
and Ghaziabad Units has been recomputed under Straight Line Method instead of
Written Down Value Method in the accounts for quarter ended June 30, 2006 and
year ended March 31, 2007 and accordingly excess depreciation amounting to Rs
60.981 millions (with corresponding deferred tax liability of Rs 20.509
millions) upto March 31, 2006 had been written back in the said quarter/year as
Non Recurring Item - Depreciation As such, figures for current quarter under
such items are not comparable with the figures of the quarter ended June 30,
2006. 5. The Statutory Auditors of the Company have carried out a Limited
Review of the results for the quarter ended June 30, 2007. 6. Figures of
previous year/period have been regrouped / rearranged wherever necessary.
KEY RATIOS
|
PARTICULARS |
31.03.2007 |
31.03.2006 |
31.03.2005 |
Debt-Equity Ratio
|
0.82 |
0.86 |
0.85 |
Long Term Debt-Equity Ratio
|
0.80 |
0.86 |
0.85 |
|
Current Ratio |
1.55 |
1.87 |
2.08 |
TURNOVER RATIOS
|
|
|
|
|
Fixed Assets |
2.09 |
2.06 |
1.99 |
Inventory
|
5.71 |
5.53 |
4.97 |
|
Debtors |
11.50 |
10.89 |
6.93 |
Interest Cover Ratio
|
6.00 |
8.91 |
4.83 |
|
Operating Profit
Margin (%) |
13.45 |
12.58 |
10.99 |
Profit Before Interest And Tax
Margin (%)
|
10.58 |
9.75 |
7.48 |
|
Cash Profit
Margin (%) |
8.42 |
8.24 |
7.27 |
|
Adjusted Net
Profit Margin (%) |
5.55 |
5.41 |
3.76 |
|
Return On Capital
Employed (%) |
23.33 |
21.72 |
15.77 |
|
Return On Net
Worth (%) |
22.23 |
22.47 |
14.64 |
STOCK PRICES
|
Face Value |
Rs.10.00 |
|
High |
Rs.95.95 |
|
Low |
Rs.90.55 |
LOCAL AGENCY FURTHER INFORMATION
HISTORY:
Incorporated in 1938 at
ADL has entered into a technical collaboration with Morishita
Pharmaceuticals,
ADL has entered into technical collaboration with
During 1998-99, the company has developed some new products viz. Siozole
Capsules and Ferrochelate-Z-Capsules with Iron & Zinc and folic acid in
sustained released formulation. In 2002-03 the company has launched new
products-INTECAR,NIMERIL-T,EVICT,ALROF-50. It is also planning to launch new
products such as SIOOXY,ALAMIN FEZ,PANSURE.
Director
Reports:
Working
results:
During the year under review, The Company achieved net Sales
of Rs.1411.621 millions and recorded a Gross Profit of Rs.194.260 millions
compared to previous year's net Sales of Rs.1168.085 millions and Gross Profit
of Rs.157.408 millions registering a growth of 20.85% and 23.42% respectively.
The consistent focus on profit generating products, introduction of some new
products and continued thrust on effective cost management has resulted in
improved and satisfactory turnover and profitability.
As reported in the last year, modernisation-cum-expansion programme in
all the manufacturing units of the Company is under progress involving capital
expenditures of about Rs.520 millions . The last phase of the above programme
is likely to be completed during the current year.
During the current year, the
Company plan for inclusion of some new products such as ALAMIN-Xtra - a
nutritional supplement, EVASTON - a gynaecological product, OPTHALMOLOGICAL
range - the Eye Care products and BETAHISTINE - the antivertigo drug.
The Company shall also be undertaking the launch of brand extension product
like ACTIBILE-SR (Actibile 450 mg.
tablets) and FERROCHELATE-XT (the new iron compound haematinic). The
Directors are hopeful of further growth in sales and better financial
performance during the current year.
DIVIDEND: :
The Directors recommend payment of dividend @ 30% on Equity shares of the
Company.
FIXED DEPOSIT: :
During the year the Company accepted fixed deposits and the balance of the
fixed deposit as on 31st March, 2007 was Rs.42.450 millions. There has not been
any unclaimed deposit outstanding as on 31st March, 2007.
DIRECTORS' RESPONSIBILITY STATEMENT :
Pursuant to sub-section
(2AA) of Section 217 of the Companies Act, 1956, the Board of Directors of the
Company hereby state and confirm that :
i) in the preparation of the annual accounts, applicable accounting
standards have been followed alongwith proper explanation relating to material
departures, if any ;
ii) the Directors had selected such accounting policies and applied them
consistently and made judgements and estimates that are reasonable and prudent
so as to give a true and fair view of the state of affairs of the Company at
the end of the financial year and of the profit of the Company for that period
;
iii) the Directors had taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the provisions of
the Companies Act, 1956 for safeguarding the assets of the Company and for
preventing and detecting fraud and other irregularities ;
iv) the Directors had prepared the annual accounts on a going concern
basis.
INFORMATION UNDER SECTION 217(2A)
AND 217(1)(e) OF THE COMPANIES ACT, 1956:
Information pursuant to The Companies (Particulars of Employees) Rules,
1975 as per Annexure-I as well as additional information in terms of Section
217(1)(e) of the Companies Act, 1956 dealing with Conservation of Energy and
Technology Absorption etc. as per Annexure-II forming part of this Report are
annexed herewith.
OUTLOOK:
Increase in healtcare awareness is expected to fuel the growth of Pharma industry. The company has undertaken range of initiatives for growth in sales in domestic and overseas market, customer development, new product development. The company is hopeful of reporting better growth in 2005-2006.
CORPORATE GOVERNANCE
:
Pursuant to Clause 49 of the Listing Agreement with the Stock Exchanges, the
Management Discussion and Analysis Report forms part of the annual Report as an
addition to the Directors' Report. Report on Corporate Governance alongwith
Auditor's Certificate thereon is also annexed to the Directors' Report.
The Auditor's Certificate and the Corporate Governance Report in compliance
with Clause 49 of the Listing Agreement are self-explanatory and do not require
further elucidation. In accordance with the requirements of revised Clause 49
of the Listing Agreement, The Board has laid down and adopted the code of
conduct for all its members and Senior Management Personnel of the
company.
Subject is in trade terms with:
· Rommeleg A.G.
Postfach,
· M.F. Marketing
B-104, Arjun Centre, BS Devashi Marg, Govandi, Mumbai – 400 088
· Gopinath Engineering Company
4, Ruchi, 36, Swastik Society,
Navrangpura, Ahmedabad – 380 009,
· Maharshi Udyog
4, Ruchi, 36. Swastik Society,
Navrangpura, Ahmedabad – 380 009,
·
Alfa Laval (
· Neel Industrial Systems Private Limited
48/3 Latif House, St. Marg,
·
Paharpur Cooling Towers,
·
Sartorious Biotech
·
Voltas Limited,
· Greaves Limited
·
Ingersoll Rand (
307 Ansal Tower 3409,
FIXED
ASSETS:
The company’s fixed assets of important value include land leasehold, buildings, machinery, tubewell, lab. equipments & fittings, furniture & fittings, office equipments, typewriter & duplicator, refrigerator & air conditioners, vehicles and computers.
WEBSITE DETAILS
ATTACHED:
Albert David, headquartered in Kolkata, is a leading, fast
growing and a professionally managed pharmaceutical company in
They
manufacture:
·
Pharmaceutical formulations and bulk drugs in their
Kolkata manufacturing unit.
·
Infusion solutions and oral solids at
·
Disposable syringes and needles at Mandideep plant
& Herbal formulations at the
·
They export these products to
·
They have DMF for the bulk drugs, Tolbutamide and
Chlorpropamide with the Food and Drugs Administration (FDA),
They
have tie-ups with:
·
World’s largest manufacturer of Amino Acids, Ajinomoto Co.
Inc. of
·
Roussel Morishita Co. of Japan for manufacturing
and marketing a wide range of Crystalline Amino Acid Infusion Solutions, Oral
solids and liquids in
Presently
they are operating in the following major therapeutic segments:
·
Analgesics
Anti Inflammatory
·
Disposable
Syringes & Needles
·
Neurotropics
·
Skeletal Relaxants Anti-Arthiritic
/ Chondroprotective Agents
·
They are pioneers in Human Placental Extract
Therapy.
·
Their marketing team comprises of about four
hundred plus professionally trained and competent sales people.
·
Their well-organised and well-connected
Distribution Network comprises of over sixteen hundred stockists’ outlets and
fifteen Sales Depots spread across the country.
·
Decades of illustrious presence in the health care
industry.
Beyond national
boundaries :
In line with their
continuing commitment to provide the best of healthcare - world wide, their
range of products are being exported all across the globe and more and more
countries are being added to the list with each passing day.
Albert David's
International dream is built on the solid foundations of technology and quality
and their relentless and dedicated fight against disease and their commitment
to excellence.
Albert David has an
evergrowing network of marketing and distribution around the world. The
international reach spreads over from S.E. Asia to
Their products being cost
effective and highly efficacious have found wide acceptance across different
continents and have been very well received.
The export department is
manned by professional people whose main objective is to provide prompt and
quality service to the overseas customer in terms of timely shipments &
timely response. It is the policy of the company to work in close unison with
its overseas customers / distributors with the aim of establishing an effective
marketing network. The company is always ready to extend full support in the
form of technical and promotional inputs for achieving the objective.
The company’s manufacturing
facilities are GMP certified by national and international agencies which is a
prime requirement for exporting to most of the world markets.
Some of their bulk drugs
are already approved by US FDA, UK MCA and European Council. Their
manufacturing units are ISO 9002 certified and the state of the art plant
manufacturing Disposable Syringes & Needles have recently got the 'CE'
Certification as well.
This is a testimony to
Albert David's commitment for quality and systems.
Albert David to set up facility to manufacture oral solids and liquids
CITY-BASED pharmaceutical company Albert David Limited, established more than seven decades ago, is planning to set up a new state-of-the-art manufacturing facility on the outskirts of the city as a part of its modernization and up gradation plans. Currently, the company manufactures and markers a wide range of pharmaceutical finished dosage form for different therapeutic segments, medical disposables and a wide-range of IV fluids.
Confirming the development, Kamal Prasad Mundhra, executive director of Albert
David Limited told Express Pharma Pulse, “The company has decided on principle to
set up a state-of-the-art manufacturing facility in and around the city”. “They
are already scouting for proper land to set up this new manufacturing facility,
which will adhere to all the international specifications like Cgmp, WHO &
FDA norms, “he informed. “We will be soon zeroing on the land and the
construction will commence immediately. The new facility to be set up at a cost
of Rs. 40 crore, is likely to come up in the next two years time, “Mundhra
added. “The new facility is likely to manufacture oral solids and liquids,
ointments and some bulk drugs. The state-of-the-art manufacturing facility will
help the to substantially bring down the per unit cost of production of
medicine”, he said.
The company has also decided to upgrade its R&D has also decided to upgrade
its R&D facilities. The new R&D facility will e housed in the proposed
manufacturing unit. Albert David Limited, is a part of the GD Kothari Group of
companies having diverse interests in textiles, engineering items, tea plantations,
chemicals, salt processing and international trading. The company’s turnover
stood at Rs. 115 crore in the last financial year (2003-04). The company
exports its products to countries in Europe, Africa and in the
In a related development, the company has also decided to increase the
production capacity of its
Albert David: A
Leader in Human Placental Extract Therapy
Albert
David Ltd., the decades old Kolkata-based leading and fast growing
professionally managed pharmaceutical company, has its eastern regional
headquarter operating in the city. Albert David has multi-centric manufacturing
plants located in Kolkata,
The
company ranked 58th out of 16,000 plus pharma companies. The
products of the company are exported to the
At
present the company is operating in major therapeutic segments like analgesics,
herbal drugs, anti-bacterials, nutrition, anti-ulcerants, neurotropics,
placental extracts, anxiolytics, small and large volume parentals,
dermatologicals and disposable syringes and needles.
Albert
David is a leader in human placental extract therapy. The company's strong
marketing team of more than 400 people has a well organized distribution
network comprising 1600 plus stockists' outlet and 15 sales depots spread
across the country
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets theyre seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial Crime
:
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or investigation
registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.40.67 |
|
|
1 |
Rs.82.12 |
|
Euro |
1 |
Rs.55.60 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
9 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
6 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
9 |
|
--PROFITABILIRY |
1~10 |
5 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
7 |
|
--RESERVES |
1~10 |
6 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
YES |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
61 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar theyight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, they have no basis upon which to
recommend credit dealings |
No Rating |
|